Follicular lymphoma · 10 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
FCR, then allo HSCT Variant #01 Partial | — | R 198 402 | — | — | — | ~1 | ~R 198 402 indirect | — |
(90)YFC, then allo HSCT Variant #01 Partial | — | R 68 878 | — | — | — | ~1 | ~R 68 878 indirect | — |
Bortezomib and Rituximab (VR) Variant #01 | — | R 58 571 | 60d | ~12.8 mo | — | ~5 | ~R 241 048 PFS proxy · indirect | 1 |
R-BEAM Variant #01 Partial | — | R 56 156 | — | — | — | ~1 | ~R 56 156 indirect | — |
R-TBI/Cy Variant #01 | — | R 52 985 | — | — | — | ~1 | ~R 52 985 indirect | — |
BEAM Variant #01 Partial | — | R 4 346 | — | — | — | ~1 | ~R 4 346 indirect | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | ~1 | ~R 1 176 PFS proxy · indirect | 2 |
Ibritumomab tiuxetan protocol Variant #18 Partial | — | — | 8d | 36.5 mo | — | 1 | — | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | — | — | 1 | — | 2 |
Observation Partial | — | — | — | 31.3 mo | — | — | — | 4 |
10 of 10 regimens shown